Fly News Breaks for March 3, 2015
XON
Mar 3, 2015 | 06:31 EDT
JPMorgan raised its price target for Intrexon to $45 saying Trans Ova drove the revenue beat in Q4. The firm notes that while the company does not issue guidance, management indicated that they expect to bring "ten novel therapeutic candidates" into the clinic in 2015. JPMorgan keeps an Overweight rating on the stock. Mizuho this morning raised its price target for Intrexon shares to $50 following the company's Q4 results.
News For XON From the Last 2 Days
There are no results for your query XON